TGFβ‐induced FOXS1 controls epithelial–mesenchymal transition and predicts a poor prognosis in liver cancer

Kevin Bévant, Matthis Desoteux, Gaëlle Angenard, Raphaël Pineau, Stefano Caruso, Corentin Louis, Panagiotis Papoutsoglou, Laurent Sulpice, David Gilot, Jessica Zucman‐Rossi, Cédric Coulouarn – 25 November 2021 – Transforming growth factor beta (TGF‐β) plays a key role in tumor progression, notably as a potent inducer of epithelial–mesenchymal transition (EMT). However, all of the molecular effectors driving TGFβ‐induced EMT are not fully characterized.

Organ‐Specific Comorbidities Are Associated With Distinct Complications After Liver Transplantation for Biliary Atresia

Sarah A. Taylor, Veena Venkat, Ronen Arnon, Vani V. Gopalareddy, Philip Rosenthal, Sarah G. Anderson, Ravinder Anand, James F. Daniel, Society of Pediatric Liver Transplantation – 24 November 2021 – Although transplant outcomes for biliary atresia (BA) have improved, there are few data to predict the risk of specific posttransplant complications. We therefore defined the impact of comorbidities in BA on posttransplant outcomes.

Pcsk9 Deletion Promotes Murine Nonalcoholic Steatohepatitis and Hepatic Carcinogenesis: Role of Cholesterol

George N. Ioannou, Sum P. Lee, Peter S. Linsley, Vivian Gersuk, Matthew M. Yeh, Yen‐Ying Chen, Yi‐Jen Peng, Moumita Dutta, Gabby Mascarinas, Bruk Molla, Julia Yue Cui, Christopher Savard – 23 November 2021 – Proprotein convertase subtilisin/kexin type 9 (Pcsk9) binds to hepatic low‐density lipoprotein receptor (LDLR) and induces its internalization and degradation. Pcsk9 inhibition increases LDLR expression by hepatocytes, which causes increased uptake of circulating LDL, thereby reducing plasma LDL‐cholesterol.

Acquired Resistance to Antiangiogenic Therapies in Hepatocellular Carcinoma Is Mediated by Yes‐Associated Protein 1 Activation and Transient Expansion of Stem‐Like Cancer Cells

Darko Castven, Carolin Czauderna, Diana Becker, Sharon Pereira, Jennifer Schmitt, Arndt Weinmann, Viral Shah, Jovana Hajduk, Friederike Keggenhoff, Harald Binder, Tobias Keck, Stefanie Heilmann‐Heimbach, Marcus A. Wörns, Snorri S. Thorgeirsson, Kai Breuhahn, Peter R. Galle, Jens U. Marquardt – 23 November 2021 – Induction of neoangiogenesis is a hallmark feature during disease progression of hepatocellular carcinoma (HCC). Antiangiogenetic compounds represent a mainstay of therapeutic approaches; however, development of chemoresistance is observed in the majority of patients.

Subscribe to